<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6408">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01728103</url>
  </required_header>
  <id_info>
    <org_study_id>ATVTS-US12-001</org_study_id>
    <secondary_id>AC2PS-US12-002</secondary_id>
    <secondary_id>ATVPS-US12-001</secondary_id>
    <secondary_id>ATVTS-US12-003</secondary_id>
    <nct_id>NCT01728103</nct_id>
  </id_info>
  <brief_title>Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays</brief_title>
  <official_title>Prospective Collection of Female First-catch Urine, Vaginal Swab,Cervical, and Endocervical Swab Specimens for Testing With the APTIMA Assays</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gen-Probe, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gen-Probe, Incorporated</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to obtain female first-catch urine, vaginal, cervical and
      endocervical swabs for testing with multiple APTIMA Assays on the Gen-Probe PANTHER® and
      TIGRIS® Systems.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Qualitative detection of ribosomal RNA from Chlamydia trachomatis and/or Neisseria gonorrhoeae (NG) and Trichomonas vaginalis (TV) to aid in the diagnosis of chlamydial and/or gonococcal and/or trichomonal urogenital disease</measure>
    <time_frame>approximately one year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2100</enrollment>
  <condition>Chlamydia Infections</condition>
  <condition>Gonorrhea</condition>
  <condition>Trichomonas Infections</condition>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>APTIMA® Trichomonas vaginalis &amp; APTIMA® COMBO 2® Assays</intervention_name>
    <description>In Vitro Diagnostic Assays</description>
    <arm_group_label>No Treatment</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      urine; endocervical and vaginal swabs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Female subjects at least 16 years of age, with or without symptoms of sexually transmitted
        disease.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is at least 16 years of age at the time of enrollment and is currently
             sexually active (has had penile/vaginal intercourse within the past 12 months)

          -  The subject and/or legally authorized representative is willing to undergo the
             informed consent process prior to study participation (a minor will need the
             documented consent of his/her parent or legal guardian, unless the site has an
             institutional review board [IRB]-approved waiver for parental consent for minors)

        In addition, the subject must meet at least one of the following criteria:

          -  The subject reports symptoms consistent with a suspected sexually transmissible
             infection (STI) such as abnormal discharge, genital itching, pain/discomfort during
             sexual intercourse or urination, and/or lower abdominal discomfort

          -  Subject is asymptomatic and known to be partners with, or a contact of, a person with
             a confirmed or suspected STI(s)

          -  Subject is asymptomatic and undergoing screening evaluation for possible STIs

          -  Subject is asymptomatic and undergoing a routine examination with a pelvic
             examination

        Exclusion Criteria:

          -  The subject took antibiotic medications within the last 21 days

          -  Subject already participated in this study

          -  Subject has a history of illness that the principal investigator (PI) or designee
             considers could interfere with or affect the conduct, results, and/or completion of
             the clinical trial

          -  Subject has a history of illness that the PI or designee considers could create an
             unacceptable risk to the subject if enrolled
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Reid, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gen-Probe, Incorporated</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patty Law, MS</last_name>
    <phone>858-731-5919</phone>
    <email>patty.law@hologic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Infectious Diseases STD Program University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles River, PhD</last_name>
      <phone>205-975-5665</phone>
      <email>rivers@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Jane Schwebke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Healthcare Clinical Data</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Clinical Research</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center Dept. of Medicine, Infectious Disease</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Camaratta</last_name>
      <phone>504-568-4132</phone>
      <email>ccamma@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilda Barnes</last_name>
      <phone>410-614-2044</phone>
      <email>mbarnes2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Charlotte Gaydos, DrPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New England Center for Clinical Research</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriane Osborn</last_name>
      <email>aosborn2@unch.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Marcia Hobbs, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arlene Seña-Soberano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center Division of Pediatric &amp; Adolescent Gynecology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Kim</last_name>
      <phone>513-636-7781</phone>
      <email>Grace.Kim@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Lea Widdice, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood Southeastern Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Jackson Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood Gulf Coast</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Farrell</last_name>
      <phone>713-831-6561</phone>
      <email>Melissa.farrell@ppgulfcoast.org</email>
    </contact>
    <investigator>
      <last_name>Paul Fine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tidewater Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 29, 2014</lastchanged_date>
  <firstreceived_date>November 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chlamydia Infections</mesh_term>
    <mesh_term>Gonorrhea</mesh_term>
    <mesh_term>Trichomonas Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
